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Abstract
Background: Adjuvant chemotherapy has been shown to improve survival rates of postoperative patients with
non-small cell lung cancer (NSCLC). Biomarkers could help select an appropriate chemotherapy for NSCLC patients
or predict the efficacy of chemotherapy. The objective of this study was to explore the possible prognostic and
predictive role of topoisomerase II alpha (TopIIa) expression level in postoperative NSCLC patients who received
adjuvant chemotherapy.
Methods: Patients with stage I-III NSCLC, who underwent surgery in our hospital from January 2004 to December
2007 and who also received adjuvant chemotherapy after surgery, were analyzed in this study. Expression of TopIIa
and Ki67 in paraffin-embedded tissues was detected by immunohistochemistry (IHC). The relationships between
clinicopathological characteristics, chemotherapy regimens, the expression of biomarkers and disease free survival
(DFS) were analyzed.
Results: TopIIa and Ki67 were highly expressed in 22.5% and 36.4% of the 151 patients, respectively. Univariate
survival analysis showed that male sex (P = 0.036), non-adenocarcinoma (P = 0.004), earlier pathological TNM stage
(P = 0.001) or pathological N stage (P < 0.001), and high expression of TopIIa (P = 0.012) were correlated with
better DFS, whereas age, smoking history, different chemotherapy regimens, T stage and expression level of Ki67
were of no prognostic significance. Further stratified analysis showed that vinorelbine (NVB)-containing adjuvant
regimens were generally associated with better DFS than regimens without NVB in patients with low TopIIa
expression, though the difference was not statistically significant (P = 0.065). Pairwise comparisons for patients with
low TopIIa expression indicated that the NVB-containing regimen was associated with better DFS than the
docetaxel (TXT)-containing regimen (P = 0.047). COX multivariate analysis showed that pathological TNM stage,
histological subtype and expression level of TopIIa to be independent of risk factors affecting DFS in postoperative
NSCLC patients who received chemotherapy.
Conclusions: High TopIIa expression was discovered to be correlated with better DFS for postoperative NSCLC
patients who received adjuvant chemotherapy. The NVB-containing chemotherapy regimen was more effective
than the TXT-containing regimen in improving DFS in patients with low TopIIa expression. TopIIa could be
considered to be an independent prognostic biomarker of DFS in postoperative NSCLC patients who received
adjuvant chemotherapy.
Background
Non-small cell lung cancer (NSCLC) remains one of the
m o s tc o m m o nc a n c e r si nC h i n aa n di nt h ew o r l d[ 1 ] .
Although surgery is the main curative treatment,
p o s t o p e r a t i v er e c u r r e n c er a n g e sf r o m3 0 %t o5 0 %[ 2 ] .
Positive results of recent clinical trials, including the Inter-
national Adjuvant Lung Cancer Trial (IALT), the National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG JBR.10) and the Adjuvant Navelbine International
Trialist Association (ANITA), provide preliminary confir-
mation on the role of adjuvant chemotherapy, showing
that platinum-based postoperative chemotherapy offers a
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any medium, provided the original work is properly cited.significant 5-year survival benefit compared with surgery
alone [3-5]. However, only 5%-15% of the individuals who
received adjuvant chemotherapy achieved long-term survi-
val improvement [6]. Therefore, it is very important to
select subgroups of patients who are most likely to benefit
from postoperative chemotherapy and who are potentially
resistant to a given chemotherapy regimen. Recent studies
have shown that expression of excision repair cross-
complementation group 1 (ERCC1), ribonucleotide reduc-
tase subunit M1 (RRM1) and class III beta-tubulin
(b-tubulinIII) could provide predictive value for patients
treated with platinum agents, gemcitabine (GEMZ) and
microtubule-interacting agents (including taxanes and
vinorelbine (NVB)), respectively [7].
Topoisomerase II alpha (TopIIa) is a nuclear enzyme
that catalyzes the conversion between DNA topological
isomers and can be detected in cells with high proliferative
activity. Many anticancer agents (i.e., anthracyclines) exert
anticancer effects by stabilizing DNA cleavage and inhibit-
ing DNA replication via binding and blocking the activity
of TopIIa [8]. TopII-inhibiting chemotherapeutic agents,
including irinotecan, etoposide and topotecan, are com-
monly used for the treatment of small cell lung cancer
(SCLC), but they are seldom used for the treatment of
NSCLC. However, it has been reported that one type of
multidrug resistance (MDR) in lung cancer, atypical MDR,
is mediated through an altered expression of TopII. This
type of resistance was found to be associated either with
decreased TopIIa expression or with a mutation that
altered the interaction of the enzyme with the drug or
DNA [9]. High TopIIa expression has been observed in
many kinds of cancers, including breast cancer and
NSCLC [10-13]. Although TopIIa expression and its
implication for TopII inhibitors have been extensively
investigated in several cancers, especially in breast cancer,
few reports have described TopIIa expression and its
cross resistance to other cytotoxic drugs in NSCLC
[10,11,14-16]. In addition, some studies have reported that
low levels of TopIIa gene or protein expression might be
related with resistance not only to TopII inhibitors, such
as etoposide and anthracycline, but also to other cytotoxic
drugs, such as cisplatin, microtubule-interacting agents
and gemcitabine, in some cancer cell lines or cancers
[17-19]. However, little is known about the correlation
between TopIIa expression, which can mediate cross
resistance, and the effect of common chemotherapy drugs,
including cisplatin, microtubule-interacting agents and
GEMZ, in postoperative NSCLC.
To assess whether TopIIa m i g h tb eav a l u a b l eb i o -
marker in postoperative NSCLC patients who received
chemotherapy, TopIIa expression levels in tumor sam-
ples were evaluated, and the prognostic and therapeutic
predictive roles of TopIIa were analyzed. Ki67, another
molecular marker that is related to proliferation, was
evaluated as a control factor.
Methods
Patient data
Patients who underwent curative surgery for NSCLC
between January 2004 and December 2007 received at
least two cycles of adjuvant chemotherapy within two
months after surgery in the General Hospital of Chinese
People’s Liberation Army (CPLA), and for whom a for-
malin-fixed, paraffin-embedded sample adequate for ana-
lysis was available, were included in the study. Patients
who received neoadjuvant chemotherapy or neoadjuvant
radiotherapy were excluded.
Data concerning clinicopathological features, including
age, sex, smoking history, histological subtypes, patholo-
gical TNM stage, surgical methods, chemotherapy regi-
mens and cycles, other treatments such as adjuvant
radiotherapy, date of recurrence or metastasis, and survi-
val information, were obtained by medical records, out-
patient and telephone follow-ups. Outcome data
including disease free survival (DFS) and overall survival
(OS) were calculated. Clinical data were kept unavailable
during immunohistochemistry (IHC). The study design
and procedure involving the human tissue sample collec-
tion were reviewed and approved by the ethical board of
the General Hospital of CPLA.
Immunohistochemistry
Representative tumor paraffin-embedded blocks were
selected and collected, after two pathologists reviewed, the
tumor sample slices stained with hematoxylin and eosin
(HE). Sections (4 μm thick) were cut from tumor speci-
mens, placed onto 3-amino-propyltriethoxy-silane (APES)
slides, and deparaffinized in xylene and gradient ethanol.
Antigen retrieval was performed by placing slides in a
high-pressure cooker in a 0.01 mM citrate buffer, pH 6.0,
for 2.5 min at 100°C; they were then cooled for 20 min.
Endogenous peroxidase activity was blocked by incubating
the section in 3% H2O2 for 10 min, followed by rinsing in
PBS solution three times. Immunohistochemical staining
was performed with the two-step EnVision(tm)+ System
Kit (Dako, Denmark). The sections were incubated with
mouse anti-TopIIa monoclonal primary antibodies (clone
3F6, 1/75 dilution, Novocastra, UK) or mouse anti-Ki67
monoclonal primary antibodies (clone MIB1, 1/200 dilu-
tion, Dako) at 37°C for 60 min, followed by dextran poly-
mer conjugated with horseradish peroxidase enzyme and
secondary anti-mouse antibody (Dako). Slides were stained
with 3,3’-diaminobenzidine tetrahydrochloride (DAB)
chromogen and counter-stained with hematoxylin. Nega-
tive controls were conducted by adding PBS solution
instead of the primary antibody, and positive controls
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our pathology specimen bank.
All the specimens were examined and scored by two
independent pathologists without the knowledge of
patient data, and their inter-observer concordance was
over 90%. The number of positive cells in 1,000 tumor
cells within 10 microscopic fields at ×200 magnification
was counted and scored as follows: 0 (negative, <25%),
1 (focal, 25% to 49%), 2 (moderate, 50% to 74% ), 3 (dif-
fuse, ≥7 5 % ) .S a m p l e sw i t hs c o r e so f0a n d1w e r ec o n -
sidered to have low expression, whereas samples of 2
and 3 were considered to have high expression.
Statistical analysis
Correlations between immunohistochemical expression
and patient or tumor characteristics were performed by
using the c
2 test or Fisher’s exact test, as appropriate. Sur-
vival curves were estimated by the Kaplan-Meier method,
and differences in DFS among groups were compared by
using the log-rank test. The COX proportional hazards
model was used for multivariate analysis to assess the
independent value of TopIIa expression. Two-sided P <
0.05 was considered statistically significant. All analyses
were performed with the SPSS 16.0 software package.
Results
Patient characteristics
We enrolled 151 eligible patients (111 male and 40
female) in this study, who ranged in age from 31 to 81
years, with a median of 55 years, of whom 86 (60%) had
a history of smoking. The main histological types
included squamous cell carcinoma (41.0%), adenocarci-
noma (39.1%), bronchioloalveolar carcinoma (10.0%),
large cell carcinoma (6.6%) and adenosquamous (3.3%).
Stage I, II and III were diagnosed in 35.8%, 31.1% and
33.1% patients, respectively. In addition, according to
pathological T stage or N stage, T1, T2, T3 and T4
were diagnosed in 25.2%, 65.5% 3.3% and 6.0% patients,
respectively, and N0, N1 and N2 were diagnosed in
41.1%, 33.1% and 25.8% patients, respectively. The
majority had undergone lobectomy (81.5%). All patients
received 2 to 8 cycles of adjuvant chemotherapy, of
whom 114 (75.5%) finished at least 4 cycles. The main
chemotherapy regimens included docetaxel (TXT,
26.5%), GEMZ (33.8%), NVB (26.5%) and paclitaxel
(PTX, 13.2%) combined with or without cisplatin
(DDP)/carboplatin (CBP). Of the 151 patients, 35
patients (23.2%), most of whom were diagnosed with
stage III or N2, received adjuvant radiotherapy. Detailed
characteristics are shown in Table 1.
TopIIa and Ki67 expression in NSCLC
TopIIa (Figure 1A and 1B) and Ki67 (Figure 1C and
1D) were located in the nucleus. TopIIa and Ki67 were
highly expressed in 22.5% and 36.4%, respectively, of all
151 patients. Additionally, the expression of TopIIa had
a strongly positive correlation with that of Ki67 (r =
0.515, P < 0.001). Table 2 shows the correlation between
TopIIa and Ki67 expression levels and clinical charac-
teristics, including sex, smoking history, histological sub-
types, pathological TNM stage, pathological T stage and
pathological N stage.
Patient outcomes and clinical predictors
After a median follow-up of 35.8 months (ranging from
16.4 - 63.7 months), 80 (53%) patients had metastatic or
recurrent tumors and 40 (26.5%) patients had died.
Causes of death were NSCLC (37 patients), radiation
pneumonitis (1 patient), appearance of a secondary
tumor (1 patient) and severe pulmonary infection
(1 patient). The median DFS of all 151 patients was 24.3
months and the median OS was not reached. The pri-
mary purpose of the study was to assess the associations
between clinical characteristics, TopIIa protein expres-
sion and efficacy of adjuvant chemotherapy. DFS was
more representative than OS as an indirect measure of
efficacy, because OS was often affected by treatments
other than adjuvant chemotherapy after recurrence or
metastasis. DFS was therefore used as the main outcome
measure in this study.
Univariate survival analysis showed that sex, pathologi-
cal TNM stage, pathological N stage, histological subtype
(adenocarcinoma or not) and TopIIa expression level
were prognostic factors related to DFS, while age, smok-
ing history, surgical methods, pathological T stage, che-
motherapy regimens and expression level of Ki67 were of
no prognostic significance. Log-rank test indicated that
male sex (P = 0.036, Figure 2A), earlier pathological
TNM stage (P = 0.001, Figure 2B) and pathological N
stage (P < 0.001), non-adenocarcinoma (P = 0.004, Figure
2C) and high TopIIa expression (P = 0.012, Figure 2D)
predicted better DFS in postoperative NSCLC patients
who received adjuvant chemotherapy. Although the P
value for comparison of the survival curves in different T
stages was less than 0.05 (P = 0.03), there was no signifi-
cant difference between T1 stage and T3-4 stage (P =
0.677) or between T2 stage and T3-4 stage (P = 0.245)
when pairwise comparisons of the three curves were per-
formed. Only the difference between T1 stage and T2
stage was significant (p = 0.011). Detailed characteristics
are also shown in Table 1.
Correlations between TopIIa expression and the value of
adjuvant chemotherapy
It was found that high expression of TopIIa was signifi-
cantly correlated with better DFS in the patients studied,
suggesting that patients with high TopIIa expression
benefited more from the adjuvant chemotherapy than
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group of patients may be a potential chemotherapy-
resistant population. Further stratified analysis of the
correlation between the value of adjuvant chemotherapy
regimens and TopIIa expression showed that when
TopIIa was highly expressed, there were no significant
differences in DFS between patients who received che-
motherapy with or without TXT (P = 0.712), with or
without NVB (P = 0.170), with or without GEMZ (P =
0.415), and with or without PTX (P = 0.763). In addi-
tion, when TopIIa expression was low, there were no
significant differences in DFS between patients who
received chemotherapy with or without TXT, with or
without GEMZ, and with or without PTX (Table 3).
However, in patients with low TopIIa expression, the
median DFS was 48.16 months for those who received
NVB-containing chemotherapy regimens and 16.23
months for those who received regimens without NVB
(P = 0.065, Figure 3A). Although this difference
was marginally insignificant, it is possible that NVB-
containing adjuvant chemotherapy is better than others
in patients with low TopIIa expression. To ascertain the
predictive value of this observation with better certainty,
the pooled comparisons as well as pairwise comparisons
of DFS among four chemotherapy subgroups were
investigated in patients with low and high TopIIa
expression. In patients with high TopIIa expression, no
significant differences in DFS were observed among the
four chemotherapy subgroups regardless of pooled or
pairwise comparisons (Table 4). In patients with low
TopIIa expression, the P value was greater than 0.05 (P
= 0.267, Figure 3B) for the pooled comparison of DFS
among the four chemotherapy subgroups. Pairwise com-
parisons of the four survival curves showed no signifi-
cant differences in P values between any two subgroups
(Table 4 and Figure 3B), except the P value between the
NVB and TXT subgroups. Pairwise comparison for low
TopIIa expression indicated that the NVB-containing
regimen was associated with better DFS than the TXT-
containing regimen (P = 0.047).
Table 1 Clinical and pathological characteristics and univariate analysis for DFS
Factors Number (%) Median DFS (months) P value
Sex male 111 (73.5) 33.99 0.036*
female 40 (26.5) 21.13
Age <55 years 74 (49.0) 21.45 0.330
≥55 years 77 (51.0) 31.97
Smoking status no 65 (43.0) 22.24 0.305
yes 86 (57.0) 32.99
Stage I 54 (35.8) NR
# 0.001*
II 47 (31.1) 33.64
III 50 (33.1) 15.18
T stage T1 38 (25.2) NR
# 0.03
T2 99 (65.5) 18.76
T3-4 14 (9.3) 38.16
N stage N0 62 (41.1) NR
# <0.001*
N1 50 (33.1) 33.64
N2 39 (25.8) 13.37
Histology Adenocarcinoma 59 (39.1) 17.41 0.004*
Non- adenocarcinoma 92 (60.9) 48.16
Surgery method Wedge resection 5 (3.3) 17.41 0.958
Lobectomy 123 (81.5) 24.41
Pneumonectomy 23 (15.2) 31.15
Chemotherapy regimens Docetaxel-containing 40 (26.5) 18.60 0.523
Vinorelbine- containing 40 (26.5) 48.16
Gemcitabine- containing 51 (33.8) 24.58
Paclitaxel- containing 20 (13.2) 24.41
TopIIa Low expression 117 (77.5) 19.38 0.012*
High expression 34 (22.5) NR
Ki67 Low expression 96 (63.6) 22.24 0.517
High expression 55 (36.4) 29.37
*P < 0.05 was considered statistically significant;
#NR = not reached.
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Multivariate analysis was performed with the COX
proportional hazards model to explore whether the prog-
nostic value of TopIIa would disappear when other com-
mon prognostic factors were considered. Correlation
analysis showed that pathological T stage and pathological
TNM stage (P < 0.001), and pathological N stage and
pathological TNM stage (P < 0.001) were mutually asso-
ciated. As pathological TNM stage is more widely
accepted as a DFS-related parameter than pathological T
stage and N stage, subsequent multivariate analysis was
performed to incorporate sex, histology, pathological
TNM stage and TopIIa expression level as covariates
based on the significance of these factors in univariate ana-
lysis. The results from the Cox proportional hazard model
using the forward stepwise method suggested that the his-
tology subtype (adenocarcinoma vs. non-adenocarcinoma),
TNM stage and the TopIIa expression level were indepen-
dent prognostic factors of DFS in NSCLC (Table 5). In
postoperative patients who received adjuvant chemother-
apy, high TopIIa expression was a prognostic marker of
longer DFS (hazard ratio 0.442, 95% confidence interval
0.239-0.818, P = 0.009), whereas adenocarcinoma (hazard
ratio 2.140, 95% confidence interval 1.373-3.337, P =
0.001) and later TNM stage (hazard ratio 1.688, 95% confi-
dence interval 1.291-2.208, P < 0.001) were related to a
shorter DFS as compared to non-adenocarcinoma and ear-
lier TNM stage.
Discussion
The results of this study suggest that high TopIIa
expression in postoperative NSCLC patients who
received adjuvant chemotherapy was associated with
better DFS. However, other studies have reported that
high TopIIa expression was associated with a poorer
survival rate in other types of tumors, including hypo-
pharyngeal carcinoma, breast cancer and salivary gland
carcinoma [20-23]. The reason for this difference is
probably that all patients in this study received adjuvant
chemotherapy while no patient received it in other stu-
dies. We therefore postulate that adjuvant chemotherapy
might overcome the adverse biology of cancers that
express higher TopIIa protein. Additionally, other
recent studies also showed that high expression or
amplification of TopIIa promised a good response to
chemotherapy, particularly to topoisomerase inhibitors,
which are partly consistent with our study [20,24]. The
results of our study imply that patients with high
TopIIa expression might be able to obtain more benefits
from adjuvant chemotherapy than those with low
TopIIa expression. Similar results were found in Sève et
al.’s study of the prognostic role of b-tubulinIII in
Figure 1 Positive expression of TopIIa and Ki67 in non-small cell lung cancer by immunohistochemistry using the EnVision two-step
method. (A) and (B) correspond to ×200 and ×400 magnification of TopIIa respectively; (C) and (D) correspond to ×200 and ×400 magnification
of Ki67 respectively.
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Clinical variables TopIIa expression (%) P Ki67 expression (%) P
High Low High Low
Sex
Male 25 (22.5) 86 (77.5) 0.998 39 (35.1) 72 (64.9) 0.584
Female 9 (22.5) 31 (77.5) 16 (40.0) 24 (60.0)
Smoking status
No 16 (24.6) 49 (75.4) 0.591 25 (38.5) 40 (61.5) 0.651
Yes 18 (20.9) 68 (79.1) 30 (34.9) 56 (65.1)
Histology
Adenocarcinoma 14 (23.7) 45 (76.3) 0.775 22 (37.3) 37 (62.7) 0.860
Non- adenocarcinoma 20 (21.7) 72 (78.3) 33 (35.9) 59 (64.1)
Stage
I 10 (18.5) 44 (81.5) 0.177 13 (24.1) 41 (75.9) 0.034*
II 15 (31.9) 32 (68.1) 23 (48.9) 24 (51.1)
III 9 (18.0) 41 (82.0) 19 (38.0) 31 (62.0)
T stage
T1 13 (34.2) 25 (65.8) 0.148 18 (47.4) 20 (52.6) 0.168
T2 18 (18.2) 81 (81.8) 34 (34.3) 65 (65.7)
T3-4 3 (21.4) 11 (78.6) 3 (21.4) 11 (78.6)
N stage
N0 12 (19.4) 50 (80.6) 0.137 16 (25.8) 46 (74.2) 0.065
N1 16 (32.0) 34 (68.0) 23 (46.0) 27 (54.0)
N2 6 (15.4) 33 (84.6) 16 (41.0) 23 (59.0)
*P < 0.05 was considered statistically significant.
Figure 2 DFS curves according to different clinical and pathological characteristics. DFS curves according to: (A) sex; (B) pathological TNM
stage; (C) histological subtype; (D) TopIIa expression level.
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high expression of b-tubulinIII was related to poor sur-
vival in the absence of adjuvant chemotherapy, though
adjuvant chemotherapy prolonged the relapse free survi-
val (RFS) and OS in patients with high b-tubulinIII
expression. Therefore, b-tubulinIII acted as not only a
prognostic biomarker of DFS but also a predictor of
response to adjuvant chemotherapy. To identify predic-
tive factors for survival benefit from treatment, an
untreated control group should be included in the
study, because a good survival identified in a single-arm
trial might simply result from prognostic factors within
the cohort, and might not be a result of treatment [26].
However, the major limitation of this study was that
patients who did not receive adjuvant chemotherapy
were not included. Therefore, we can merely draw the
conclusion that TopIIa acted as a prognostic biomarker
of DFS in the postoperative NSCLC patients who
received adjuvant chemotherapy. A further study includ-
ing patients with and without adjuvant chemotherapy is
required to clarify the predictive role of TopIIa with
r e s p e c tt ot h eb e n e f i to fa d j u v a n tc h e m o t h e r a p y .
Moreover, TopIIa exhibited an independent significantly
prognostic role for DFS, when common prognostic fac-
tors, including pathological TNM stage and histological
subtype, were considered in multivariate analysis. In
addition, the positive correlation between the expression
of TopIIa and that of Ki67, as observed in this study, is
consistent with prior published reports in NSCLC and
breast cancer [13,27,28]. It suggests that higher TopIIa
expression is associated with higher cell proliferation in
NSCLC, as is the case with Ki67, which is a known cell
proliferation marker. Although expression of Ki67 had a
strongly positive correlation with expression of TopIIa,
Ki67 was of no prognostic significance to DFS.
This is the first study reporting the evaluation of differ-
ent adjuvant chemotherapy regimens by TopIIa expres-
sion level in NSCLC. We found that NVB-containing
regimens were associated with better DFS than those
without NVB in patients with low TopIIa expression,
although the P value was marginally insignificant (P =
0.065). These results are concordant with previous
reports related to the mechanism of atypical MDR, which
is mediated by TopIIa showing that atypical MDR exhib-
ited cross resistance to many anticancer drugs, except
vinca alkaloids [29,30]. However, the result of pooled and
pairwise comparisons of DFS between the four che-
motherapy subgroups for low or high TopIIa expression
showed that only the difference between the NVB and
TXT subgroups was significant in patients with low
TopIIa expression (P = 0.047). Therefore, it can be
deduced that patients with low TopIIa expression are a
possible MDR population and that NVB-containing regi-
mens may be better than TXT-containing regimens in
these patients. Although there is no sufficient evidence
that the efficacy of NVB is better than that of GEMZ and
PTX in patients with low TopIIa expression, DFS of the
NVB subgroup was no worse than that of the GEMZ and
Table 3 Comparison of DFS among different
chemotherapy groups in patients with low TopIIa
expression
Chemotherapy regimens Number Median DFS (months) P
Vinorelbine Containing 29 48.16 0.065
Not containing 88 16.23
Gemcitabine Containing 39 14.13 0.530
Not containing 78 22.74
Docetaxel Containing 33 15.74 0.194
Not containing 84 22.74
Paclitaxel Containing 16 22.97 0.990
Not containing 101 18.76
Figure 3 Comparison of DFS rates among different chemotherapy subgroups in patients with low TopIIa expression.( A )d e p i c t s
comparison of DFS curves between the NVB regimen group and the group of other regimens without NVB; (B) depicts comparison of DFS
curves among four chemotherapy subgroups.
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high TopIIa expression, there were no significant differ-
ences in DFS between the different regimens no matter
what grouping or comparison methods were performed.
Several studies have indicated that high TopIIa expres-
sion was a positive predictive factor for response to
anthracycline-based chemotherapy in patients with pri-
mary breast cancer [31,32]. It is well known that anthra-
cycline in an anti-topoisomerase drug, and should exert
strong anti-cancer activity in patients with high TopIIa
expression. However, further study is needed to deter-
mine whether an anti-topoisomerase-based adjuvant che-
motherapy such as etoposide can really bring more
benefits to postoperative NSCLC patients with high
TopIIa expression than other chemotherapy regimens.
Owing to the limitations of retrospective research,
the conclusions drawn from this study need to be
further identified and validated in prospective clinical
trials. Another deficiency of this study is that the med-
ian OS was not reached due to limited follow-up time.
Considering that the connection between TopIIa
expression and adjuvant chemotherapy was the main
purpose of this study, DFS was more representative
than OS for evaluating efficacy. Moreover, OS could
be influenced by many factors in this retrospective
study, which may possibly lead to a negative result for
long-term survival. Prospective randomized clinical
trials with larger sampling capacities and longer fol-
low-up periods are needed to shed more light on the
real relationship between TopIIa expression and the
benefit from the given chemotherapy.
This study demonstrated a significant association
between TopIIa expression and DFS, in which high
TopIIa expression was associated with better DFS than
low TopIIa expression, and NVB-containing adjuvant
regimens were probably better than TXT-containing
regimens in the low TopIIa e x p r e s s o r s .T h u s ,T o p I I a
may be a good biomarker to predict the value of adjuvant
chemotherapy, although further validation is required.
Conclusions
In conclusion, TopIIa expression is an independent
prognostic factor of DFS in postoperative NSCLC
patients who received adjuvant chemotherapy. Low
expression of TopIIa is related to poor DFS. NVB-con-
taining adjuvant regimens are probably better than
TXT-containing regimens in patients with low TopIIa
expression. However, further investigation is needed to
confirm the significance of TopIIa as a prognostic or
predictive biomarker before these conclusions can be
translated into clinical practice.
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Table 4 Pooled and pairwise comparisons of DFS among four chemotherapy regimens in patients with different
TopIIa expression levels
TopIIa expression Chemotherapy regimens Vinorelbine (P) Gemcitabine (P) Docetaxel (P) Paclitaxel (P) P for each stratum
Low expression stratum Vinorelbine 0.128 0.047* 0.322 0.267
Gemcitabine 0.128 0.676 0.786
Docetaxel 0.047* 0.676 0.429
Paclitaxel 0.322 0.786 0.429
High expression stratum Vinorelbine 0.209 0.410 0.437 0.594
Gemcitabine 0.209 0.895 0.902
Docetaxel 0.410 0.895 0.987
Paclitaxel 0.437 0.902 0.987
*P < 0.05 was considered statistically significant.
Table 5 Multivariate analysis for factors related to DFS
using the COX proportional hazard model
Factors Wald Hazard
ratio
95% CI P
Sex 0.903 0.784 0.474 - 1.295 0.342
Histology
(adenocarcinoma)
11.277 2.140 1.373 - 3.337 0.001*
TNM stage (later) 14.631 1.688 1.291 - 2.208 <0.001*
Topoisomerase II alpha
expression
(high expression)
6.773 0.442 0.239 - 0.818 0.009*
*P < 0.05 was considered statistically significant.
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